Tim_Biotech @BiotechTechBio

AWS needs to stop charging for 4xx requests to s3 buckets immediately. In GitHub here are 63k references to us-east-1 buckets alone. Anyone can start racking up massive bills for these users with a simple PUT request! This is insane: medium.com/@maciej.pocwie…

57 225 2K 516K 643

View Details

David Galbraith @daveg

2 years ago

Wake up Europe, the digital age is bypassing you. You have no Google , Amazon, Meta, Apple. You arrogantly called SpaceX a fanciful dream and it wiped out the European Space Agency. You have no Nvidia and your response to AI has been to regulate before you have anything domestic to regulate. Your car industry is about to be wiped out by the Chinese. Your biggest economy shut down nuclear out of spite and with fraud. Your capital markets have no liquidity and your startups are drowning in bureaucracy. Your border is being attacked by Russia and your defence spending will have to triple just to be where it was with US subsidy given that part of the former Soviet Union and the Eastern bloc is now part of the EU. Your economy has slumped from the world’s largest to way behind the US. Your pensions are paid by three times less people and cost five times as much as people live longer. Your infrastructure is a model for the world but is configured for rail over self drive. Your electricity grid needs half a trillion of investment to cope with planned capacity and replacements, for the switch to renewables, within a decade. There are bright spots such as pharma and your healthcare system is a model for what civilisation looks like it. But to afford it, you need to completely transform from the industrial to digital age, to reform your institutions and rout the sclerotic bureaucratic system.

Rodolfo Rosini ✨🖥️ @rodolfor

2 years ago

Anyway speaking of dirigiste failure, here's another banger. Going from calling reusable rockets a dream to not having a space industry in 10 years. Good job guys!

39 172 2K 2.3M 363

769 3K 14K 6.3M 5K

View Details

Matt Dancho (Business Science) @mdancho84

2 years ago

Python has a vast ecosystem of AI tools and libraries. The problem is it's confusing. So I spent 24 hours putting together a cheat sheet that captures every Python library I use most frequently. Over the past 6 months I’ve been quietly building dozens of new AI projects that can help data scientists become AI experts for their company. Through this process, I’ve used 100s of AI tools. And it’s become increasingly clear that the AI ecosystem is large and changing daily. So I decided to centralize the tools and python libraries that I’m using most frequently for AI. On May 30th, I will give away my new Python for Generative AI cheat sheet as part of my live AI course launch and training event. Want the new Python AI cheat sheet? 👉 Register and attend live (all attendees will get the cheat sheet): learn.business-science.io/python-generat…

3 72 313 20K 253

View Details

Paras Sharma @paras_biotech

2 years ago

World of ADC: PFE is ahead however NVS, Lilly, Gilead, JNJ and Amgen lagging behind. Graph From Guggenheim

2 28 118 32K 80

View Details

Time Capsule Tales @timecaptales

2 years ago

Colorful towns & cities with the best views from above - a thread 1. Venice, Italy 🇮🇹

202 4K 60K 13.7M 12K

View Details

@

2 years ago

🧵My Deep Diver into $RXRX Here we will look at the sum of the parts for @RecursionPharma

2 7 33 20K 26

View Details

Dennis X. Hu @DennisWhom

2 years ago

BIOTECH VS. PHARMA A biotech is a pharma company that’s “unencumbered” by revenue. That can mean more focus, greater speed, and more flexibility.. ..but it can also mean fewer resources, less institutional knowledge, and more risk. Our friends in biotech find awe in the Manhattan Project-level initiatives our pharma friends can tackle - think Pfizer’s 1 yr Paxlovid sprint or Merck’s decades-long PCSK9 program. Sometimes the feeling is, “we couldn’t afford to do that here.” Our friends in pharma are envious of the novel technologies that biotechs get to use first. Biotechs got to use DEL, degraders, mRNA display, RNA modulation, and so much more first. Sometimes the feeling is, “we would’ve done that if management hadn’t stopped us.” Biotechs are incredible places to learn by doing. I got my first project leadership opportunity two years into the job.. but only because everyone else quit! Pharmas are incredible places to learn from others. You can walk down the hall and find the world’s leading expert on virtually any indication, approach, or program. Biotechs may have fewer total resources, but you don’t have to beg for them for your project. If a biotech chooses to work on something, it’s likely going to see it through to the clinic. Often, there’s no other choice - your CEO will want to know the status of the project at lunch. Pharma may have more total resources, but they’re rarely yours. Need an expensive study for your project? You’ll likely need to set up several meetings to bargain for it with other departments. Don’t mess up the pre-meeting alignment meeting, or your budget request might get torpedoed. Our biotech members appreciate Drug Hunter as an alternative to the journal clubs, experienced colleagues, and knowledge resources they had in pharma. With Drug Hunter, they can see what’s going on throughout the industry and learn about new targets, technologies, and approaches to drug discovery without spending a fortune on subscriptions and conferences. Our pharma members appreciate Drug Hunter as a window outside their silos, to understand what areas are increasingly hot, what technologies are being validated, and to continue their education in drug discovery with the precious little time they have between meetings or on the commute. One commented that she didn’t even realize her company had a certain research program until she saw it on Drug Hunter! The grass is always greener in different ways, but everyone in biotech and pharma wants to see their molecules become helpful medicines. Would love to hear more experiences from throughout the industry!